U.S. INJECTABLE COMPOUNDING PHARMACY MARKET ANALYSIS

U.S. Injectable Compounding Pharmacy Market, By Molecule (Acetaminophen, Phenylephrine, Midazolam, Esmolol, Vancomycin, Epinephrine, Adenocaine, Fentanyl/Bupivacaine, Morphine, Amiodarone, Fentanyl, Heparin, Ketamine, Dextrose, Hydromorphone, Bupivacaine, Lidocaine, BKK (Bupivacaine, Ketorolac, Ketamine), RCK (Ropivacaine, Clonidine, Ketorolac), RKK (Ropivacaine, Ketorolac, Ketamine), Norepinephrine, Diltiazem, Vasopressin, Others), By Packaging Type (Vials, Ampoules, Prefilled Syringes, Others), By Pharmacy Type (503A Pharmacies, 503B Pharmacies)

U.S. Injectable Compounding Pharmacy Market: Key Developments

In June 2023, the U.S. FDA registered 503B outsourcing company Leiters Health, which offers pharmacy services and compounded sterile preparations, announced the rebranding of its business to better reflect the company’s expanding market dominance in the healthcare industry and planned strategic growth. A new corporate logo, Quality Compounding for Life, and a name change to Leiters Health are the three main components of this rebranding.
In July 2020, Piramal Critical Care (PCC), a manufacturer of inhalation anesthesia products, entered into a strategic partnership with Medivant Healthcare, a U.S.-based pharmaceutical outsourcing facility, for addressing severe shortage of injectable drugs in hospitals across the U.S. The companies focused on the distribution of single-dose injectable drugs in all approved states of the U.S. that had fallen dangerously in shortage of the supply of drugs, for the treatment of COVID-19 patients.

U.S. Injectable Compounding Pharmacy Market Report Snapshots